Rising Tide/LUNGevity Team Award Program to Target Mechanisms of Resistance 2023 RFA

Projects funded are expected to further our knowledge of shared mechanisms of resistance across oncogene-driven LUAD and how they can be targeted using novel pharmaceutical agents (monotherapies or combination therapies). . All projects will need to address shared mechanisms across 3-4 oncogene driven LUADs. Projects that focus on one type of oncogene-driven LUAD will not be funded through this mechanism.

This is a team award and at least two institutions are required to be involved right from the LOI stage. One institution must be based in the USA.